India is poised to reject Shanghai Fosun Pharmaceutical Group Co.’s proposed $1.3 billion takeover of an Indian drugmaker, according to people familiar with the matter, scuppering the biggest-ever Chinese acquisition in the country. The Cabinet Committee on Economic Affairs, which is chaired by Prime Minister Narendra Modi, has decided to block the Chinese firm’s purchase of an 86 percent stake in Gland Pharma Ltd., according to the people. The companies haven’t been formally notified yet of the move, the people said, asking not to be identified because the information is private.
Tensions between China and India have escalated amid a renewed spat over territory in a remote area of the Himalayas, one of the most serious flareups between the two Asian giants since a border war in 1962. A collapse of the acquisition would be a setback for Fosun Pharma, which had sought Gland Pharma’s stable of generic injectable medicines and facilities approved to manufacture products for sale in the U.S. Read More…
Credit By: Financial Express
Latest posts by Financial Express (see all)
- Have Probed 33 Coal Cases For 2006-2009 Allocation: CBI To Supreme Court – October 17, 2017
- Railways Announce Faster, Cheaper Delhi To Mumbai Rajdhani Express For Diwali – October 14, 2017
- Tata Steel, JSW Steel, 2 Foreign Firms Show Interest In Bhushan Power And Steel, Bhushan Steel – October 12, 2017